(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.

The three biggest winners today are INDLE FIN.ENTREPR., INTEROIL EXPL PROD, and NYXOAH.

Financial Asset	Price	Change	Updated (EST)
INDLE FIN.ENTREPR. (INFE.PA)	94.50	70.27%	2023-11-10 13:04:47
INTEROIL EXPL PROD (IOX.OL)	0.79	20.61%	2023-11-10 12:40:36
NYXOAH (NYXH.BR)	5.26	11.91%	2023-11-10 12:20:57
CUMULEX (CLEX.BR)	1.54	10%	2023-11-10 12:05:32
BEAULIEU-AV. CERT (BEAB.BR)	3.54	9.94%	2023-11-10 12:04:56
METABOLIC EXPLORER (METEX.PA)	0.57	8.65%	2023-11-10 13:20:21
PCI BIOTECH HOLD (PCIB.OL)	2.50	7.78%	2023-11-10 12:42:04
MAREL (MAREL.AS)	2.33	7.37%	2023-11-10 12:02:48
VALNEVA (VLA.PA)	6.77	7.33%	2023-11-10 13:24:04
AKER BIOMARINE (AKBM.OL)	44.75	7.31%	2023-11-10 12:24:15

The three biggest losers today are ATENOR, ORPEA, and EQUASENS.

Financial Asset	Price	Change	Updated (EST)
ATENOR (ATEB.BR)	10.90	-17.42%	2023-11-10 12:04:48
ORPEA (ORP.PA)	1.16	-17.37%	2023-11-10 13:20:59
EQUASENS (EQS.PA)	58.40	-15.48%	2023-11-10 13:02:30
BORGESTAD (BOR.OL)	0.32	-11.94%	2023-11-10 12:25:00
HOFSETH BIOCARE (HBC.OL)	2.60	-10.65%	2023-11-10 12:40:28
QUESTERRE ENERGY (QEC.OL)	1.59	-9.84%	2023-11-10 12:42:23
NEL (NEL.OL)	7.31	-9.6%	2023-11-10 12:41:21
LATECOERE (LAT.PA)	0.11	-8.33%	2023-11-10 13:05:22
AF GRUPPEN (AFG.OL)	112.40	-8.32%	2023-11-10 12:24:06
NORSKE SKOG (NSKOG.OL)	39.42	-8.2%	2023-11-10 12:41:31

Winners today

1. INDLE FIN.ENTREPR. (INFE.PA)

70.27% Price Change

Compagnie Industrielle et Financière d'Entreprises SA operates as a construction company in France. It undertakes maritime and river, underwater, structures and civil engineering, buildings, and other special works. The company also develops real estate properties. Compagnie Industrielle et Financière d'Entreprises SA was founded in 1913 and is headquartered in Saint-Herblain, France. The company is a subsidiary of Alfred de Musset SAS.

CAC 40 ended the session with INDLE FIN.ENTREPR. jumping 70.27% to €94.50 on Friday while CAC 40 slid 0.96% to €7,045.04.

Earnings Per Share

As for profitability, INDLE FIN.ENTREPR. has a trailing twelve months EPS of €4.78.

PE Ratio

INDLE FIN.ENTREPR. has a trailing twelve months price to earnings ratio of 19.77. Meaning, the purchaser of the share is investing €19.77 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.21%.

Moving Average

INDLE FIN.ENTREPR.’s worth is way above its 50-day moving average of €58.78 and way above its 200-day moving average of €57.33.

Yearly Top and Bottom Value

INDLE FIN.ENTREPR.’s stock is valued at €94.50 at 21:40 EST, way above its 52-week high of €70.00.

Volume

Today’s last reported volume for INDLE FIN.ENTREPR. is 299 which is 1200% above its average volume of 23.

Revenue Growth

Year-on-year quarterly revenue growth grew by 27.3%, now sitting on 250.05M for the twelve trailing months.

More news about INDLE FIN.ENTREPR..

2. INTEROIL EXPL PROD (IOX.OL)

20.61% Price Change

Interoil Exploration and Production ASA, together with its subsidiaries, operates as an upstream oil exploration and production company. It engages in the acquisition, exploration, development, and operation of oil and natural gas properties. The company's portfolio includes two producing concessions and two exploration concessions in Colombia; and one exploration and seven production concessions in Argentina. Interoil Exploration and Production ASA was incorporated in 2005 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with INTEROIL EXPL PROD jumping 20.61% to €0.79 on Friday, after four successive sessions in a row of losses. Oslo Børs Benchmark Index_GI dropped 0.43% to €1,283.07, after two sequential sessions in a row of gains, on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, INTEROIL EXPL PROD has a trailing twelve months EPS of kr-0.32.

Revenue Growth

Year-on-year quarterly revenue growth declined by 41.7%, now sitting on 14.09M for the twelve trailing months.

Volatility

INTEROIL EXPL PROD’s last week, last month’s, and last quarter’s current intraday variation average was a negative 9.48%, a positive 0.47%, and a positive 4.73%.

INTEROIL EXPL PROD’s highest amplitude of average volatility was 9.48% (last week), 7.48% (last month), and 4.73% (last quarter).

Moving Average

INTEROIL EXPL PROD’s value is way higher than its 50-day moving average of kr0.63 and under its 200-day moving average of kr0.82.

Earnings Before Interest, Taxes, Depreciation, and Amortization

INTEROIL EXPL PROD’s EBITDA is 13.39.

More news about INTEROIL EXPL PROD.

3. NYXOAH (NYXH.BR)

11.91% Price Change

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

BEL 20 ended the session with NYXOAH rising 11.91% to €5.26 on Friday while BEL 20 fell 1.15% to €3,438.86.

Earnings Per Share

As for profitability, NYXOAH has a trailing twelve months EPS of €-1.66.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -34.86%.

More news about NYXOAH.

4. CUMULEX (CLEX.BR)

10% Price Change

Cumulex N.V. does not have significant operations. Previously, the company was engaged in sugar plantation business in the Democratic Republic of Congo. The company was formerly known as Sucrerie et Raffinerie de l'Afrique Centrale NV and changed its name to Cumulex N.V. in March 2021. The company was founded in 1956 and is based in Diegem, Belgium. Cumulex N.V. is a subsidiary of Value8 NV.

BEL 20 ended the session with CUMULEX rising 10% to €1.54 on Friday while BEL 20 dropped 1.15% to €3,438.86.

Earnings Per Share

As for profitability, CUMULEX has a trailing twelve months EPS of €-0.23.

Volume

Today’s last reported volume for CUMULEX is 7 which is 75.86% below its average volume of 29.

Volatility

CUMULEX’s last week, last month’s, and last quarter’s current intraday variation average was a negative 42.86%, a negative 20.30%, and a positive 37.08%.

CUMULEX’s highest amplitude of average volatility was 42.86% (last week), 53.89% (last month), and 37.08% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CUMULEX’s stock is considered to be overbought (>=80).

More news about CUMULEX.

5. BEAULIEU-AV. CERT (BEAB.BR)

9.94% Price Change

Immo-Beaulieu NV owns and operates real estate properties. The company is based in Brussels, Belgium. Immo-Beaulieu NV operates as a subsidiary of KBC Bank NV.

BEL 20 ended the session with BEAULIEU-AV. CERT rising 9.94% to €3.54 on Friday while BEL 20 dropped 1.15% to €3,438.86.

More news about BEAULIEU-AV. CERT.

6. METABOLIC EXPLORER (METEX.PA)

8.65% Price Change

METabolic EXplorer S.A., a biological chemistry company, engages in the development and industrialization of industrial fermentation processes as alternatives to petrochemical processes worldwide. The company also offers propanediol, butyric acid, butyric acid, glycolic acid, amino acid, and L-Valine. Its products are used in the formulation of cosmetics, textiles, polymer, animal nutrition, and health products or as intermediates for the synthesis of biomaterials. The company was incorporated in 1999 and is based in Saint-Beauzire, France.

CAC 40 ended the session with METABOLIC EXPLORER rising 8.65% to €0.57 on Friday while CAC 40 fell 0.96% to €7,045.04.

Earnings Per Share

As for profitability, METABOLIC EXPLORER has a trailing twelve months EPS of €-0.98.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -42.82%.

Moving Average

METABOLIC EXPLORER’s worth is way above its 50-day moving average of €0.51 and way below its 200-day moving average of €0.94.

Volatility

METABOLIC EXPLORER’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.01%, a negative 1.13%, and a positive 6.00%.

METABOLIC EXPLORER’s highest amplitude of average volatility was 15.17% (last week), 9.02% (last month), and 6.00% (last quarter).

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on Jan 1, 1970, the estimated forward annual dividend yield is 0.04%.

Yearly Top and Bottom Value

METABOLIC EXPLORER’s stock is valued at €0.57 at 21:40 EST, way under its 52-week high of €1.95 and way above its 52-week low of €0.22.

More news about METABOLIC EXPLORER.

7. PCI BIOTECH HOLD (PCIB.OL)

7.78% Price Change

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in pre-clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Olix Pharmaceuticals, Aposense, IMV Immunovaccine, MDimune, eTheRNA, and Immunicum. PCI Biotech Holding ASA was incorporated in 2007 and is based in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with PCI BIOTECH HOLD jumping 7.78% to €2.50 on Friday while Oslo Børs Benchmark Index_GI dropped 0.43% to €1,283.07.

Earnings Per Share

As for profitability, PCI BIOTECH HOLD has a trailing twelve months EPS of kr-0.79.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -47.54%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, PCI BIOTECH HOLD’s stock is considered to be overbought (>=80).

Earnings Before Interest, Taxes, Depreciation, and Amortization

PCI BIOTECH HOLD’s EBITDA is -4.54.

More news about PCI BIOTECH HOLD.

8. MAREL (MAREL.AS)

7.37% Price Change

Marel hf. develops, distributes, and sells solutions, software, and services to food processing industries in Europe, the Middle East, Africa, the Americas, Asia, and Oceania. The company's Poultry Processing segment offers integrated systems, software, and services for processing broilers, turkeys, and ducks. Its Meat Processing segment supplies primary, secondary, and further processing equipment, systems, software, and services of pork, beef, veal, and sheep. The company's Fish Processing segment offers equipment, systems, software, and services for farmed and wild salmon and whitefish processing. Its Plant, pet and feed segment provides solutions and services to the pet food, plant-based protein, and aqua feed markets. Marel hf. was founded in 1977 and is based in Garðabær, Iceland.

AEX-Index ended the session with MAREL jumping 7.37% to €2.33 on Friday, after two sequential sessions in a row of losses. AEX-Index dropped 0.38% to €746.31, following the last session’s upward trend on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, MAREL has a trailing twelve months EPS of €0.05.

PE Ratio

MAREL has a trailing twelve months price to earnings ratio of 46.6. Meaning, the purchaser of the share is investing €46.6 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.87%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 6.3%, now sitting on 1.81B for the twelve trailing months.

Volume

Today’s last reported volume for MAREL is 372248 which is 430.73% above its average volume of 70138.

Sales Growth

MAREL’s sales growth is 20.4% for the current quarter and 6.3% for the next.

More news about MAREL.

9. VALNEVA (VLA.PA)

7.33% Price Change

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

CAC 40 ended the session with VALNEVA rising 7.33% to €6.77 on Friday, after three sequential sessions in a row of gains. CAC 40 fell 0.96% to €7,045.04, after two consecutive sessions in a row of gains, on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, VALNEVA has a trailing twelve months EPS of €0.09.

PE Ratio

VALNEVA has a trailing twelve months price to earnings ratio of 75.2. Meaning, the purchaser of the share is investing €75.2 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.81%.

Volatility

VALNEVA’s last week, last month’s, and last quarter’s current intraday variation average was 1.58%, 0.63%, and 1.99%.

VALNEVA’s highest amplitude of average volatility was 2.97% (last week), 2.36% (last month), and 1.99% (last quarter).

More news about VALNEVA.

10. AKER BIOMARINE (AKBM.OL)

7.31% Price Change

Aker BioMarine AS engages in the offshore harvesting and production, logistical operations, and onshore manufacturing and sales of krill-derived products for nutraceutical, pet food, and aquaculture industries in Norway, the Americas, the Asia Pacific, Europe, the Middle East, and Africa. It operates through two segments, Ingredients and Brands. It provides Superba, a krill oil; QRILL Aqua, an ingredient for formulated feeds; and QRILL Pet, a functional marine ingredient for pets. The company also offers LYSOVETA, a supplement product for brain health; Understory, a protein peptides product; and PL+, a delivery platform for human health sector. In addition, it distributes human health and nutrition products, and natural supplements, as well as provides AION, a circular solution provider that recycles plastic streams and biological residue. The company was founded in 2006 and is headquartered in Lysaker, Norway. Aker BioMarine ASA is a subsidiary of Aker ASA.

Oslo Børs Benchmark Index_GI ended the session with AKER BIOMARINE rising 7.31% to €44.75 on Friday while Oslo Børs Benchmark Index_GI dropped 0.43% to €1,283.07.

Earnings Per Share

As for profitability, AKER BIOMARINE has a trailing twelve months EPS of kr-2.69.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.16%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is a negative 93.9% and a negative 67.7%, respectively.

More news about AKER BIOMARINE.

Losers Today

1. ATENOR (ATEB.BR)

-17.42% Price Change

Atenor SA, a real estate development company, invests in large-scale real estate projects in Belgium, Luxembourg, the Netherlands, France, Germany, Portugal, Poland, Hungary, the United Kingdom, and Romania. The company develops real estate projects, such as offices and residential buildings. Atenor SA was founded in 1910 and is headquartered in La Hulpe, Belgium.

BEL 20 ended the session with ATENOR falling 17.42% to €10.90 on Friday while BEL 20 fell 1.15% to €3,438.86.

Earnings Per Share

As for profitability, ATENOR has a trailing twelve months EPS of €-9.45.

Volatility

ATENOR’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.02%, a positive 0.15%, and a positive 4.25%.

ATENOR’s highest amplitude of average volatility was 2.49% (last week), 3.18% (last month), and 4.25% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ATENOR’s stock is considered to be overbought (>=80).

Volume

Today’s last reported volume for ATENOR is 22732 which is 204.75% above its average volume of 7459.

More news about ATENOR.

2. ORPEA (ORP.PA)

-17.37% Price Change

ORPEA SA operates nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, and psychiatric hospitals. Its nursing home facilities provide personalized support services; and logistical and residential services, including accommodation, meals, and laundry and room cleaning, as well as various daily event, entertainment, and therapeutic workshop services. The company's post-acute and rehabilitation hospitals offer services for geriatrics, musculoskeletal, nervous system, cardiovascular, hematology, and oncology conditions, as well as patients in a persistent vegetative state or in a minimally conscious state. Its psychiatric hospitals provide services for the patients with mood disorders, anxiety disorders, obsessive-compulsive disorders, addictions, eating disorders, sleep disorders, personality disorders, ageing-related psychiatric disorders, psychosis, over exhaustion or burn-out, chronic fatigue syndrome, fibromyalgia, psychosomatic conditions, and post-traumatic stress disorder conditions, as well as geriatric, child, young adult, parent-child, and public/private patients psychiatry services. In addition, the company offers home care services, including housekeeping services, such as cleaning, meals, ironing, gardening, and household errands; daily life assistance services comprising day or night supervision, assistance with hygiene tasks, and meal-time assistance; and movement assistance services. The company operates in France, Belgium, Spain, Italy, Ireland, Switzerland, Austria, Germany, the Czech Republic, Poland, the Netherlands, Luxembourg, Portugal, Brazil, Russia, Slovenia, Uruguay, Colombia, Mexico, Chile, Latvia, Croatia, and China. ORPEA SA was founded in 1989 and is headquartered in Puteaux, France.

CAC 40 ended the session with ORPEA dropping 17.37% to €1.16 on Friday, after two sequential sessions in a row of gains. CAC 40 dropped 0.96% to €7,045.04, after two successive sessions in a row of gains, on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, ORPEA has a trailing twelve months EPS of €-63.9.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -445.48%.

Yearly Top and Bottom Value

ORPEA’s stock is valued at €1.16 at 21:40 EST, way below its 52-week high of €9.49 and way higher than its 52-week low of €0.87.

Volatility

ORPEA’s last week, last month’s, and last quarter’s current intraday variation average was a positive 9.14%, a negative 0.05%, and a positive 4.27%.

ORPEA’s highest amplitude of average volatility was 14.98% (last week), 6.83% (last month), and 4.27% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ORPEA’s stock is considered to be oversold (<=20).

More news about ORPEA.

3. EQUASENS (EQS.PA)

-15.48% Price Change

Equasens Société anonyme provides healthcare IT solutions in Europe. It offers id. PATIENT, a business software; id. MOBILITY, a back-office management software; pandaLAB Pro, an instant messaging solution; Id. VENTE, an HAS-certified drug database; Id. COMMANDE, an order management module; dispensing robots; Services Ségur id; id. DOSAGE, a dosage management and printing module; multimeds reconditioning robot; compliance monitoring module; home delivery module; home equipment rental management module; Visiodroits module; and Website connector. The company also provides id. DESK, an informative and interactive dashboard; id. UP!, a real-time monitoring and control application of id management software; id. EASYQ, a queue management solution; Miaterapia; Id. SHOW, an application for managing real-time communications on pharmacy screens; Pharmaweb; TsGatePro; LMO, a dispensary business software; and LGO, a dispensary management software. In addition, it offers DOMILINK HAD software; mobiSOINS mobility tool; MEMORialis, support software for alzheimer's monitoring teams; HOSPILINK, an hospital information system applications; HOSPILINK DPI, a computerized patient file; HOSPILINK LOOKUP Big Data; eNephro solutions; NOVIAcare solutions; KAP&LINK2, a contact chip card reader terminal and NFC reader; eS-KAP-Ad, a connected nomadic tool incorporating software; KAP-INSIDE, a mobile terminal; and TI-KAP allowing access to contact and contactless cards. Further, the company provides AUTHENTICATOR, a patented authentication system; KAP'TEUR by KAPELSE, a patented universal sensor; ExpressVitale; MédiStory, that automates the transfer of invoicing to the healthcare professional's accounting. Additionally, it offers medical telesecretarial services for healthcare professionals, as well as equipment lease financing solutions. The company was incorporated in 1996 and is headquartered in Villers-les-Nancy, France. Equasens Société anonyme is a subsidiary of Marque Verte Sante.

CAC 40 ended the session with EQUASENS sliding 15.48% to €58.40 on Friday while CAC 40 slid 0.96% to €7,045.04.

Earnings Per Share

As for profitability, EQUASENS has a trailing twelve months EPS of €3.05.

PE Ratio

EQUASENS has a trailing twelve months price to earnings ratio of 19.15. Meaning, the purchaser of the share is investing €19.15 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.25%.

More news about EQUASENS.

4. BORGESTAD (BOR.OL)

-11.94% Price Change

Borgestad ASA develops, manufactures, distributes, and installs refractory products in Norway. The company also develops and manages real estate properties. Its properties include Agora Bytom, a shopping center with a gross area of 52,000 square meters and a rental area of approximately 30,000 square meters, as well as a parking garage with 820 parking lots in Poland. Borgestad ASA was founded in 1904 and is headquartered in Skien, Norway.

Oslo Børs Benchmark Index_GI ended the session with BORGESTAD falling 11.94% to €0.32 on Friday, following the last session’s downward trend. Oslo Børs Benchmark Index_GI fell 0.43% to €1,283.07, after two successive sessions in a row of gains, on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, BORGESTAD has a trailing twelve months EPS of kr-1.12.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -15.11%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 400% and 100%, respectively.

Earnings Before Interest, Taxes, Depreciation, and Amortization

BORGESTAD’s EBITDA is 122.4.

Moving Average

BORGESTAD’s worth is way below its 50-day moving average of kr1.50 and way below its 200-day moving average of kr1.46.

More news about BORGESTAD.

5. HOFSETH BIOCARE (HBC.OL)

-10.65% Price Change

Hofseth BioCare ASA operates as a consumer and pet health ingredient supplier in Norway and internationally. Its products include Brilliant salmon oil; OmeGo salmon oil for the maintenance of healthy cholesterol, joint, eye, brain, and cardiovascular function; ProGo, a salmon protein hydrolysate powder for treatment of irondeficiency anaemia, irritable bowel syndrome, and sarcopenia; CalGo, a marine calcium powder produced to support cartilage function, joint health, and bone strength; CollaGo; and PetGo, a non-soluble protein. Hofseth BioCare ASA was incorporated in 2009 and is headquartered in Ålesund, Norway.

Oslo Børs Benchmark Index_GI ended the session with HOFSETH BIOCARE falling 10.65% to €2.60 on Friday while Oslo Børs Benchmark Index_GI slid 0.43% to €1,283.07.

Earnings Per Share

As for profitability, HOFSETH BIOCARE has a trailing twelve months EPS of kr-0.28.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -108.36%.

Volatility

HOFSETH BIOCARE’s last week, last month’s, and last quarter’s current intraday variation average was 1.29%, 0.06%, and 1.95%.

HOFSETH BIOCARE’s highest amplitude of average volatility was 1.29% (last week), 1.80% (last month), and 1.95% (last quarter).

More news about HOFSETH BIOCARE.

6. QUESTERRE ENERGY (QEC.OL)

-9.84% Price Change

Questerre Energy Corporation acquires, explores, and develops non-conventional oil and gas projects in Canada. It produces tight oil, oil shale, shale oil, and shale gas. The company primarily holds 40,960 acres located in Kakwa, west central Alberta, including a 25% working interest in 10,080 acres in Kakwa Central; 50% working interest in 4,480 acres in Kakwa North; 50% interest in 22,400 acres in Kakwa West; and 50% interest in 3,840 acres in Kakwa South. It also holds 100% working interest in 11,035 acres located in Antler, Saskatchewan; and oil shale assets in Jordan. The company was formerly known as Westpro Equipment Ltd. and changed its name to Questerre Energy Corporation in December 2000. The company was incorporated in 1971 and is headquartered in Calgary, Canada.

Oslo Børs Benchmark Index_GI ended the session with QUESTERRE ENERGY dropping 9.84% to €1.59 on Friday, following the last session’s upward trend. Oslo Børs Benchmark Index_GI fell 0.43% to €1,283.07, after two successive sessions in a row of gains, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, QUESTERRE ENERGY has a trailing twelve months EPS of kr0.08.

PE Ratio

QUESTERRE ENERGY has a trailing twelve months price to earnings ratio of 19.93. Meaning, the purchaser of the share is investing kr19.93 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.18%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

QUESTERRE ENERGY’s EBITDA is 101.41.

More news about QUESTERRE ENERGY.

7. NEL (NEL.OL)

-9.6% Price Change

Nel ASA, a hydrogen company, provides various solutions to produce, store, and distribute hydrogen from renewable energy in Norway and internationally. The company operates in two segments, Nel Hydrogen Fueling and Nel Hydrogen Electrolyser. The Nel Hydrogen Fueling segment produces H2Station hydrogen fueling stations that provide fuel cell electric vehicles with the fueling and long range as conventional fossil fuel vehicles, include cars, buses, trucks, and other applications. The Nel Hydrogen Electrolyser segment supplies hydrogen production equipment based on alkaline and proton exchange membrane water electrolysis technology. It serves industry, energy, and gas companies. The company was formerly known as DiaGenic ASA and changed its name to Nel ASA in October 2014. Nel ASA was founded in 1927 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with NEL sliding 9.6% to €7.31 on Friday, following the last session’s upward trend. Oslo Børs Benchmark Index_GI fell 0.43% to €1,283.07, after two consecutive sessions in a row of gains, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, NEL has a trailing twelve months EPS of kr-0.93.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -23.62%.

More news about NEL.

8. LATECOERE (LAT.PA)

-8.33% Price Change

Latécoère S.A. designs, manufactures, assembles, and installs aerostructures and interconnection systems in Europe, the United States, Africa, Asia, and internationally. The company operates through Aerostructures and Interconnection systems segments. It also supplies doors, fuselage, wings, empennage, and connecting rods, as well as manufactures wing sub-assemblies and fuselage components, such as sections, tail cones, front fairings, and watertight bulkheads. In addition, the company offers interconnection systems components comprising of avionics racks, test benches, EWIS and space harnesses; cameras, screens, data transmission solutions; and other electronics. The company was founded in 1917 and is headquartered in Toulouse, France. Latécoère S.A. is a subsidiary of SCP SKN HOLDING I SAS.

CAC 40 ended the session with LATECOERE sliding 8.33% to €0.11 on Friday, following the last session’s upward trend. CAC 40 dropped 0.96% to €7,045.04, after two successive sessions in a row of gains, on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, LATECOERE has a trailing twelve months EPS of €-8.26.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -311.52%.

More news about LATECOERE.

9. AF GRUPPEN (AFG.OL)

-8.32% Price Change

AF Gruppen ASA, a contracting and industrial company, provides civil engineering, environmental, construction, property, energy, and offshore services in Norway and Sweden. It offers civil engineering services including construction of various projects, such as roads, rail, airports, foundation work, building, fitting, and securing tunnels; and oil and gas installation services, and port facilities, as well as provides concrete technology, groundwork and earthmoving, geomatics and surveying, and project support services. The company also operates as a turnkey contractor that includes development and planning to buildings comprising residential, commercial, public buildings, and rehabilitation and rebuilding, as well as offers extension work services. In addition, it provides energy solutions, which includes energy performing contracting, technical turnkey contract, local power supply, and technical services and maintenance, as well as energy solutions for existing and new buildings. Further, the company engages in operation of construction and decommissioning projects including removal and recycling of offshore installations; and offers cooling and ventilation for onshore and offshore installations, rigs, and ships, as well as offshore wind services. It also operates as a contractor for demolition and environmental clean-up services for buildings and structures, such as blasting, dredging, handling of contaminated bulk material, and removal of shipwrecks. Additionally, the company provides office spaces on rental basis, and sale of homes. AF Gruppen ASA was founded in 1985 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with AF GRUPPEN dropping 8.32% to €112.40 on Friday, following the last session’s upward trend. Oslo Børs Benchmark Index_GI slid 0.43% to €1,283.07, after two consecutive sessions in a row of gains, on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, AF GRUPPEN has a trailing twelve months EPS of kr6.58.

PE Ratio

AF GRUPPEN has a trailing twelve months price to earnings ratio of 17.08. Meaning, the purchaser of the share is investing kr17.08 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.7%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

AF GRUPPEN’s EBITDA is 145.08.

Revenue Growth

Year-on-year quarterly revenue growth grew by 8.6%, now sitting on 31.72B for the twelve trailing months.

More news about AF GRUPPEN.

10. NORSKE SKOG (NSKOG.OL)

-8.2% Price Change

Norske Skog ASA produces and sells newsprint and magazine papers. It operates in two segments, Publication Paper Europe, and Publication Paper Australasia. The company offers standard newsprint and other papers; and magazine paper comprising super calendared and lightweight coated magazine paper. Its products are primarily used in newspapers and magazines, catalogues, advertising materials, inserts/flyers, supplements, free-sheets, directories, direct mail, and book papers. The company operates in Norway, rest of Europe, North America, Australasia, Asia, and Africa. Norske Skog ASA was founded in 1962 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with NORSKE SKOG dropping 8.2% to €39.42 on Friday while Oslo Børs Benchmark Index_GI fell 0.43% to €1,283.07.

Earnings Per Share

As for profitability, NORSKE SKOG has a trailing twelve months EPS of kr9.75.

PE Ratio

NORSKE SKOG has a trailing twelve months price to earnings ratio of 4.04. Meaning, the purchaser of the share is investing kr4.04 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.82%.

More news about NORSKE SKOG.

Stay up to date with our winners and losers daily report